Australia allows entry to the country for those with the Sinopharm vaccine
Australia’s drug regulatory agency, Therapeutic Products Administration, announced that it recognizes BBIBP-CorV COVID-19 vaccines developed by Sinopharm of China and Covaxin vaccines produced by Bharat Biotech of India.
Australia’s drug regulatory agency, Therapeutic Products Administration, announced that it recognizes BBIBP-CorV COVID-19 vaccines developed by Sinopharm of China and Covaxin vaccines produced by Bharat Biotech of India.
The Therapeutic Goods Administration (TGA), Australia’s drug regulatory agency, announced that passengers who have BBIBP-CorV and Covaxin vaccines, which are not yet in use in Australia but are widely applied in many countries, will be accepted as fully vaccinated when they enter the country with the opening of the Australian borders.
Explaining that the vaccines in question provide protection against the virus and that they have obtained additional information showing that a potential inbound passenger reduces the possibility of transmitting the infection to others or getting sick due to Kovid-19 while in Australia, TGA stated that they decided to recognize the vaccines, taking into account the information given by the World Health Organization. .
In Australia, where vaccines developed by AstraZeneca, Pfizer-BioNTech and Moderna are implemented, 77.5 percent of the population over the age of 16 who are eligible for the vaccine receives a double dose vaccine, while the rate of those who receive a single dose has reached 88.3%.
Source Chinese International Radio
Hibya News Agency
